Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scanner aims to sharpen cancer radiation targeting

NCT ID NCT06576908

Knowledge-focused Sponsor: Varian, a Siemens Healthineers Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new on-couch imaging system called HyperSight, which takes 3D X-ray pictures (CBCT) of cancer patients right before their radiation treatment. 46 adults with head/neck, chest, abdomen, or pelvic cancers received both the new HyperSight scan and a standard scan on their first, second, and last days of radiation. The goal was to compare image quality and see if the new system could provide clearer pictures to help doctors aim radiation more accurately.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HyperSight imaging device
What this could lead to
If successful, this imaging technology could help doctors see tumors more clearly during radiation treatment, potentially leading to more precise targeting and fewer side effects.
What could go wrong
This is a small, completed imaging study that only assessed image quality, not treatment outcomes. Better images may not always translate into better patient results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Started

Oct 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient age is ≥ 18 years old. * Patient has a diagnosis of primary or metastatic cancer, including but not limited to tumors arising from or involving the head/neck, lungs, liver, pancreas, prostate, urinary bladder, rectum, cervix or uterus. * A previous (standard-of-care) decision was made to treat the patient with radiation therapy using a Varian TrueBeam treatment system. * A previous (standard-of-care) decision was made to treat the patient with a radiation dose of at least 20 Gy in at least 5 fractions, one fraction per day on consecutive days, Monday to Friday. * Patient is willing and able to provide informed consent to participate in the study. Exclusion Criteria: * Patient is pregnant or has plans for pregnancy during the period of treatment. * Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer head and neck cancer Head and Neck Neoplasms Pelvic Neoplasms thoracic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal cancer Head and neck cancer Pelvic cancer Thoracic cancer

Contacts and locations

Locations

  • Princess Margaret Cancer Centre (University Health Network)

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.